Comparison of expired carbon monoxide and plasma cotinine as markers of cigarette abstinence
- PMID: 18650033
- PMCID: PMC2577604
- DOI: 10.1016/j.drugalcdep.2008.05.013
Comparison of expired carbon monoxide and plasma cotinine as markers of cigarette abstinence
Abstract
The clinical pharmacology of biochemical measures of nicotine exposure has been thoroughly reviewed with regard to usefulness and limitations in detecting abstinence from cigarette smoking. While plasma nicotine concentration measures only acute nicotine exposure, plasma, salivary, and urine cotinine concentrations reflect exposure over an extended period of time. Although, expired carbon monoxide (CO) is frequently used to confirm self reports, it has a relatively short half life, calling into question whether this measure might provide misleading information by exaggerating smoking cessation success rates. To examine this question, we analyzed expired CO, plasma cotinine and self report data collected in a clinical trial in which subjects (N=207) were randomly assigned to gain- or loss-framed messages for smoking cessation in combination with open label sustained-release bupropion (300 mg/day). In examining measurements collected at 6 weeks, 3 and 6 months, results showed that CO significantly overestimated abstinence rates as compared with cotinine, although the discrepancy was less at the later time points. These data suggest that while expired CO is a useful and well-established marker in certain contexts, when testing extended abstinence from smoking with non-nicotine medications, cotinine measurements should be preferred.
References
-
- Acosta MC, Buchhalter AR, Breland AB, Hamilton DCP, Eissenberg T. Urine cotinine as an index of smoking status in smokers during 96-hr abstinence: Comparison between gas chromatography/mass spectrometry and immunoassay test strips. Nicotine Tob Res. 2004;6:615–620. - PubMed
-
- Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: A randomized controlled trial. J Am Med Assoc. 2002;288:468–474. - PubMed
-
- Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: A randomized placebo-controlled trial. Addiction. 2004;99:1206–1218. - PubMed
-
- Brandon TH, Copeland AL, Saper ZL. Programmed therapeutic messages as a smoking treatment adjunct: Reducing the impact of negative affect. Health Psychol. 1995;14:41–47. - PubMed
-
- Brown RA, Burgess SA, Sales SD, Whiteley JA, Evans DM, Miller IW. Reliability and validity of a smoking Timeline Followback interview. Psychol Addict Behav. 1998;12:101–112.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical